HRD

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

Retrieved on: 
星期二, 五月 7, 2024
Oncology, Health, Genetics, Health Technology, Research, Science, Breast cancer, HRD, Cancer, Pancreatic cancer, Partnership, Genetic testing, Prostate cancer, BRCA, CICF, Patient, Physician, Medicine, Ovarian cancer, AstraZeneca, Tutoring

Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.

Key Points: 
  • Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.
  • Eligible patients in both the private and public sectors can apply for the free genetic tests through their physicians.
  • The program will offer BRCA or HRD testing to eligible patients diagnosed with breast cancer and ovarian cancer, prostate cancer and pancreatic cancer.
  • "We are proud to leverage our cutting-edge technology and expertise to offer free genetic testing services to eligible cancer patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO of Inocras Hong Kong Limited.

SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)

Retrieved on: 
星期三, 四月 17, 2024
HRD, Sophia Genetics, Laboratory, GENETICS, Machine learning, Artificial intelligence, NGS, HRR, DNA, Science, Patient, Neoplasm, Medicine, Ovarian cancer, FAMH

BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.

Key Points: 
  • Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.
  • Founded in 1987 in Switzerland, Unilabs conducts more than 221 million tests annually across its laboratories, imaging centers, and collection centers.
  • "SOPHiA GENETICS' AI-based technology is at the forefront of where precision medicine is going – blending science and technology to deliver the best possible outcomes for patients.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on X , LinkedIn , Facebook , and Instagram .

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
星期二, 三月 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Inocras to Present Enhancing Genomic Analysis in Cancer Diagnostics at the 2024 AACR Annual Meeting

Retrieved on: 
星期五, 四月 5, 2024
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, WGS, FF, Algorithm, TMB, Tissue, Cancer, AACR, Whole genome sequencing, HRD, Poster, Multimedia, Machine learning, Artifact, Therapy, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240405427133/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405427133/en/
    Inocras presenting at the 2024 American Association for Cancer Research (AACR 2024) in San Diego, USA.
  • Our research findings presented at AACR 2024 will underscore the potential of machine learning in revolutionizing personalized cancer treatment strategies."
  • Inocras's participation in AACR 2024 showcases the company's relentless dedication to leveraging technological innovation to revolutionize cancer research and clinical practice.
  • For more information about Inocras and its groundbreaking research presented at AACR 2024, please visit Inocras.

Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists

Retrieved on: 
星期二, 三月 12, 2024
Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Database, Genetic testing, Disease, Intelligence, Risk, Library, Patient, RNA, DNA, Cancer, Medicine, Genome, Biology, Clinical trial, Neoplasm, Genomics, Liquid biopsy, HRD, Therapy, Collection, Physician

Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Key Points: 
  • Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.
  • As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext® and CancerNext-Expanded® assays.
  • “Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing.
  • Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard.

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

Retrieved on: 
星期一, 三月 11, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, PARP1, Senior, HRD, Medicine, University, CNS, Patient, MD Anderson Cancer Center, PARP, Therapy, Cancer, Safety, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.
  • SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.
  • In preclinical models, selective PARP1 targeting has been shown to improve both the efficacy and safety of the class.
  • “Dosing of the first patient in the SNV1521 Phase I trial is a key milestone as Synnovation transitions from a preclinical to clinical stage biotech company.

Renowned Human Resources Development Expert Dr. TV Rao Joins Coacharya's Advisory Board to Bring Coaching to Educational Institutions

Retrieved on: 
星期三, 三月 27, 2024
Organization, Learning, Partnership, Education, Indian Institutes of Management, Central Waqf Council, Father, Leadership development, Jaipur Rugs, Human resources, Feedback, HRD, Training and development, Tutoring

LOS ANGELES, March 27, 2024 /PRNewswire/ -- Coacharya, a leading provider of accredited coach training and coaching programs, proudly announces the appointment of Dr. TV Rao, a distinguished Human Resource Development (HRD) leader, to its esteemed Board of Advisors. 

Key Points: 
  • Widely acknowledged as one of the "Fathers of Human Resources Development in India," Dr. Rao's influential contributions include pioneering a groundbreaking Leadership Development methodology.
  • "At Coacharya, we are thrilled to welcome Dr. TV Rao to our Board of Advisors.
  • His extensive experience and visionary leadership in Human Resource Development align seamlessly with our commitment to democratizing coaching, particularly in educational institutions.
  • Coacharya's commitment to democratizing coaching aligns seamlessly with Dr. TV Rao's mission of institutionalizing coaching in educational institutions.

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
星期三, 三月 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
星期六, 三月 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Retrieved on: 
星期二, 三月 12, 2024
MSD, PARG, Apoptosis, Prostate cancer, Endometrial cancer, Colorectal cancer, RECIST, Patient, MSI, Merck & Co., Pembrolizumab, Medicine, MSS, Breast cancer, HRD, Therapy, ADP, PD-1, Pharmaceutical industry

"We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.

Key Points: 
  • "We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.
  • "We are very pleased to collaborate with Merck on this trial evaluating IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer.
  • Under the clinical trial collaboration and supply agreement, Merck will provide KEYTRUDA to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial.
  • The mechanistic rationale and preclinical data to support the IDE161 and PD-1 clinical combination will be provided as part of a future R&D update.